Status:
COMPLETED
Minocycline Treatment in Retinitis Pigmentosa
Lead Sponsor:
Sun Yat-sen University
Conditions:
Retinitis Pigmentosa
Inherited Retinal Dystrophy
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).
Detailed Description
Retinitis Pigmentosa (RP)is a sort of inherited blinding disorders and no effective or safe treatment are widely applied for it. The worldwide prevalence of RP is estimated to be 1/5000. RP is charact...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Retinitis Pigmentosa: nyctalopia, visual field constriction and loss of central vision; degeneration of peripheral rod photoreceptor and retinal pigment epithelium cells.
- Age from 18 to 60 years old.
- BCVA \>20/100(0.2) at least in one eye.
- Full-field cone electroretinogram amplitude to 30-Hz flashes \>0uV at least in one eye.
- Written informed consent is provided.
Exclusion
- Glucocortticoids or tetracycline were used within 3 months.
- Vitamin A, DHA and other neurotrophic drugs were used within 3 months.
- Other ocular diseases or fundus diseases except cataract: glaucoma, diabetic retinopathy, retinal detachment.
- Tetracycline or minocycline allergy or intolerance.
- Renal or hepatic insufficiency.
- History of thyroid neoplasm.
- History of idiopathic intracranial hypertension.
- Pregnant or lactating females.
Key Trial Info
Start Date :
August 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04068207
Start Date
August 25 2019
End Date
December 1 2023
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, China, 510060